Back to top

Cerus' soars on meeting main goal of late stage trial for INTERCEPT RBCs in heart surgery patients

Cerus' soars on meeting main goal of late stage trial for INTERCEPT RBCs in heart surgery patients

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Cerus Corporation (CERS)